Newamsterdam Pharma Stock Investor Sentiment

NAMS Stock   23.87  0.20  0.83%   
Slightly above 68% of NewAmsterdam Pharma's investor base is looking to short. The analysis of the overall investor sentiment regarding NewAmsterdam Pharma suggests that many traders are alarmed. NewAmsterdam Pharma's investing sentiment can be driven by a variety of factors including economic data, NewAmsterdam Pharma's earnings reports, geopolitical events, and overall market trends.

Comfort Level 32

 Alarmed

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use NewAmsterdam Pharma's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward NewAmsterdam Pharma.

NewAmsterdam Historical Sentiment

Although NewAmsterdam Pharma's investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding NewAmsterdam, such as negative comments on social media and news outlets, may cause fear in the market and push NewAmsterdam Pharma's investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of NewAmsterdam.
  

NewAmsterdam Pharma Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards NewAmsterdam Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

NewAmsterdam Pharma Historical Investor Sentiment

Investor biases related to NewAmsterdam Pharma's public news can be used to forecast risks associated with an investment in NewAmsterdam. The trend in average sentiment can be used to explain how an investor holding NewAmsterdam can time the market purely based on public headlines and social activities around NewAmsterdam Pharma. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
NewAmsterdam Pharma's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for NewAmsterdam Pharma and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average NewAmsterdam Pharma news discussions. The higher the estimate score, the more favorable the investor's outlook on NewAmsterdam Pharma.

NewAmsterdam Pharma Maximum Pain Price Across May 16th 2025 Option Contracts

NewAmsterdam Pharma's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of NewAmsterdam Pharma close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of NewAmsterdam Pharma's options.
a day ago at thelincolnianonline.com         
NewAmsterdam Pharma Trading 3.4 percent Higher Time to Buy?
news
few days ago at news.google.com         
Newamsterdam Pharma COO Kling sells 2.36 million in stock - Investing.com India
Google News at Macroaxis
few days ago at www.macroaxis.com         
Disposition of 100000 shares by Douglas Kling of NewAmsterdam Pharma at 23.16 subject to Rule 16b-3
Macroaxis News
over a week ago at news.google.com         
9,983 Shares in NewAmsterdam Pharma Purchased by Keybank National Association OH - Defense World
Google News at Macroaxis
over a week ago at thelincolnianonline.com         
Insider Buying NewAmsterdam Pharma Director Acquires 84,185.10 in Stock
news
over a week ago at thelincolnianonline.com         
NewAmsterdam Pharma Sees Strong Trading Volume After Insider Buying Activity
news
over two weeks ago at news.google.com         
Newamsterdam pharma director James Topper buys 84,203 in shares - Investing.com
Google News at Macroaxis
over two weeks ago at news.google.com         
New Amsterdam Pharma chief accounting officer sells 3.06 million in shares - Investing.com
Google News at Macroaxis
over two weeks ago at www.macroaxis.com         
Disposition of 150000 shares by Louise Kooij of NewAmsterdam Pharma at 20.37 subject to Rule 16b-3
Macroaxis News
over two weeks ago at www.macroaxis.com         
Disposition of 8914 shares by Douglas Kling of NewAmsterdam Pharma at 21.33 subject to Rule 16b-3
Macroaxis News
over two weeks ago at finance.yahoo.com         
NewAmsterdam Pharma Company N.V. Yearly Results Heres What Analysts Are Forecasting For This Year
Yahoo News
over two weeks ago at thelincolnianonline.com         
NewAmsterdam Pharma Announces Quarterly Earnings Results
news
over two weeks ago at gurufocus.com         
Decoding NewAmsterdam Pharma Co NV A Strategic SWOT Insight
Gurufocus Stories at Macroaxis
over three weeks ago at simplywall.st         
Companies Like NewAmsterdam Pharma Are In A Position To Invest In Growth
Simply Wall St News at Macroaxis
over three weeks ago at finance.yahoo.com         
NewAmsterdam Pharma Full Year 2024 Earnings Revenues Beat Expectations, EPS Lags
Yahoo News
Far too much social signal, news, headlines, and media speculation about NewAmsterdam Pharma that are available to investors today. That information is available publicly through NewAmsterdam media outlets and privately through word of mouth or via NewAmsterdam internal channels. However, regardless of the origin, that massive amount of NewAmsterdam data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of NewAmsterdam Pharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of NewAmsterdam Pharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to NewAmsterdam Pharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive NewAmsterdam Pharma alpha.

NewAmsterdam Pharma Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 25132 shares by Forgrowth Nap B.v. of NewAmsterdam Pharma at 25.4904 subject to Rule 16b-3
12/23/2024
2
Disposition of 16164 shares by Forgrowth Nap B.v. of NewAmsterdam Pharma at 25.66 subject to Rule 16b-3
12/24/2024
3
Disposition of 33438 shares by Forgrowth Nap B.v. of NewAmsterdam Pharma at 26.0072 subject to Rule 16b-3
12/26/2024
4
Disposition of 41472 shares by Forgrowth Nap B.v. of NewAmsterdam Pharma at 25.9522 subject to Rule 16b-3
12/27/2024
5
Acquisition by Kastelein Johannes Jacob Pieter of 200000 shares of NewAmsterdam Pharma at 25.96 subject to Rule 16b-3
01/02/2025
6
Acquisition by Davidson Michael H. of 670467 shares of NewAmsterdam Pharma at 25.85 subject to Rule 16b-3
01/06/2025
7
Acquisition by Mayur Somaiya of 38000 shares of NewAmsterdam Pharma subject to Rule 16b-3
01/07/2025
8
Acquisition by Smither John W of 6960 shares of NewAmsterdam Pharma subject to Rule 16b-3
01/08/2025
9
Acquisition by Van Der Kamp Hilde Johanna of 6960 shares of NewAmsterdam Pharma subject to Rule 16b-3
01/21/2025
10
Disposition of 23815 shares by Douglas Kling of NewAmsterdam Pharma at 23.46 subject to Rule 16b-3
01/27/2025
11
Disposition of 5148 shares by Douglas Kling of NewAmsterdam Pharma at 21.93 subject to Rule 16b-3
01/28/2025
12
Disposition of 13578 shares by Douglas Kling of NewAmsterdam Pharma subject to Rule 16b-3
01/31/2025
13
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635
02/07/2025
14
Both private equity firms who control a good portion of NewAmsterdam Pharma Company N.V. along with institutions must be dismayed after last weeks 8.1 percent d...
02/14/2025
15
Disposition of 90782 shares by Douglas Kling of NewAmsterdam Pharma at 19.54 subject to Rule 16b-3
02/18/2025
16
Disposition of 9218 shares by Douglas Kling of NewAmsterdam Pharma at 19.23 subject to Rule 16b-3
02/19/2025
17
NewAmsterdam Pharma Co NV Announces Participation in Key Investor Conferences
02/25/2025
18
NewAmsterdam Pharma Co NV Reports 2024 Financial Results and Provides Corporate Update
02/26/2025
19
NewAmsterdam Pharma Announces Quarterly Earnings Results
02/28/2025
20
Disposition of 150000 shares by Louise Kooij of NewAmsterdam Pharma at 20.37 subject to Rule 16b-3
03/04/2025
21
Newamsterdam pharma director James Topper buys 84,203 in shares - Investing.com
03/06/2025
22
9,983 Shares in NewAmsterdam Pharma Purchased by Keybank National Association OH - Defense World
03/12/2025
23
Disposition of 100000 shares by Douglas Kling of NewAmsterdam Pharma at 23.16 subject to Rule 16b-3
03/17/2025

Additional Tools for NewAmsterdam Stock Analysis

When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.